Vinay Prasad

Associate Professor

  • 2078 Citations
  • 23 h-Index
20092018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Neoplasms Medicine & Life Sciences
Conflict of Interest Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Drug Approval Medicine & Life Sciences
Medicine Medicine & Life Sciences
United States Food and Drug Administration Medicine & Life Sciences
Evidence-Based Medicine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2009 2018

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

Hernandez, I., Prasad, V. & Gellad, W. F., Jan 1 2018, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalArticle

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis
1 Citations

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

Nishikawa, G., Luo, J. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 143-151 9 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms
History
Drug Therapy
Conflict of Interest

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Prasad, V., McCabe, C. & Mailankody, S., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Costs and Cost Analysis

A pooled analysis of published, basket trials in cancer medicine

Hazim, A. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 244-250 7 p.

Research output: Contribution to journalArticle

Medicine
Neoplasms
Fallopian Tube Neoplasms
Thymus Neoplasms
Seminoma

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Shanbhag, S. & Prasad, V., Nov 1 2018, In : European Journal of Cancer. 104, p. 252-253 2 p.

Research output: Contribution to journalLetter

Hodgkin Disease
Costs and Cost Analysis
cAC10-vcMMAE